News & Updates

Wearable sensor patch reliably predicts worsening heart failure

17 Mar 2020 by

A novel, wearable heart failure (HF) patch accurately predicted worsening HF and impending rehospitalization days before the event actually happened in adults who were recently discharged from hospitalization for HF (HHF), according to the LINK-HF* study.

Wearable sensor patch reliably predicts worsening heart failure

17 Mar 2020

Ultra-low dose estriol vaginal gel effective against vulvovaginal atrophy

17 Mar 2020

Treatment with the ultra-low dose 0.005% estriol vaginal gel yields improvements in symptoms and signs of vulvovaginal atrophy, with minimal oscillations in hormonal levels, according to the results of a phase II trial.

Ultra-low dose estriol vaginal gel effective against vulvovaginal atrophy

17 Mar 2020

Apixaban better than rivaroxaban in routine care of patients with atrial fibrillation

17 Mar 2020

Incidence of ischaemic stroke or systemic embolism is lower in adults with atrial fibrillation treated with apixaban than those prescribed rivaroxaban, results of a recent study have shown.

Apixaban better than rivaroxaban in routine care of patients with atrial fibrillation

17 Mar 2020

SPIRIT-P1: Ixekizumab suitable for long-term treatment of psoriatic arthritis

17 Mar 2020 by

Ixekizumab induces early and durable improvements in psoriatic arthritis (PsA) patients naïve to biological disease-modifying antirheumatic drugs (bDMARDs), with response occurring as early as week 1 and persisting throughout 3 years of treatment without incremental safety risks, according to the results of the phase III SPIRIT-P1* trial.

SPIRIT-P1: Ixekizumab suitable for long-term treatment of psoriatic arthritis

17 Mar 2020

Original New Drug Application Approvals by US FDA (01 - 15 March 2020)

17 Mar 2020

New drug applications approved by US FDA as of 01 - 15 March 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01 - 15 March 2020)

17 Mar 2020

Wearable brain stimulation shows promise for motor function recovery after stroke

16 Mar 2020 by

A novel, noninvasive wearable brain stimulation device that delivers continuous transcranial magnetic stimulation to induce the brain to rewire itself significantly increases brain activity and is safe in patients with chronic ischaemic stroke — thus presenting a step forward to improving motor function after stroke, suggests a preliminary study presented at ISC 2020 Meeting.

Wearable brain stimulation shows promise for motor function recovery after stroke

16 Mar 2020

Longer dual anti-HER2 therapy may improve response in HER2+ breast cancer

16 Mar 2020

A 24-week course of dual anti-HER2 treatment produces a numeric increase in response rates compared with a 12-week course without using chemotherapy in women with breast cancer harbouring a HER2 mutation, according to the results of a phase II trial.

Longer dual anti-HER2 therapy may improve response in HER2+ breast cancer

16 Mar 2020

Statin exposure following THA/TKA reduces risk of revision arthroplasty

15 Mar 2020

The risk of revision arthroplasty can be reduced by initiating statin therapy up to 5 years following total hip/knee arthroplasty (THA/TKA), suggests a recent study.

Statin exposure following THA/TKA reduces risk of revision arthroplasty

15 Mar 2020

Gabapentin useful as alternative treatment for vasomotor symptoms

15 Mar 2020

Gabapentin is beneficial in the treatment of vasomotor symptoms in postmenopausal women with contraindications to hormonal therapy or who prefer alternatives, according to the results of a systematic review and meta-analysis.

Gabapentin useful as alternative treatment for vasomotor symptoms

15 Mar 2020

Add-on ipragliflozin safe, effective for type 1 diabetes in the long run

15 Mar 2020

Ipragliflozin, as an add-on therapy to insulin, appears to have good long-term efficacy in type 1 diabetes mellitus patients, reports a new Japan study.

Add-on ipragliflozin safe, effective for type 1 diabetes in the long run

15 Mar 2020

News & Updates

Filter by Specialty:

Specialty:

Wearable sensor patch reliably predicts worsening heart failure

Wearable sensor patch reliably predicts worsening heart failure

Ultra-low dose estriol vaginal gel effective against vulvovaginal atrophy

Ultra-low dose estriol vaginal gel effective against vulvovaginal atrophy

Apixaban better than rivaroxaban in routine care of patients with atrial fibrillation

Apixaban better than rivaroxaban in routine care of patients with atrial fibrillation

SPIRIT-P1: Ixekizumab suitable for long-term treatment of psoriatic arthritis

SPIRIT-P1: Ixekizumab suitable for long-term treatment of psoriatic arthritis

Original New Drug Application Approvals by US FDA (01 - 15 March 2020)

Original New Drug Application Approvals by US FDA (01 - 15 March 2020)

Wearable brain stimulation shows promise for motor function recovery after stroke

Wearable brain stimulation shows promise for motor function recovery after stroke

Longer dual anti-HER2 therapy may improve response in HER2+ breast cancer

Longer dual anti-HER2 therapy may improve response in HER2+ breast cancer

Statin exposure following THA/TKA reduces risk of revision arthroplasty

Statin exposure following THA/TKA reduces risk of revision arthroplasty

Gabapentin useful as alternative treatment for vasomotor symptoms

Gabapentin useful as alternative treatment for vasomotor symptoms

Add-on ipragliflozin safe, effective for type 1 diabetes in the long run

Add-on ipragliflozin safe, effective for type 1 diabetes in the long run